China Life Insurance (Overseas) Company Limited (CHILOV)

China Life Overseas remains an investment-grade-oriented regional life-insurance credit, supported by an established Hong Kong-Macau franchise, strategic group ownership and A-range ratings displayed by the Company. The direction of the central credit view is broadly stable rather than rapidly improving: the newly published Macau Branch statements provide current audited evidence of substantial local premium volume, profitability and investment assets, but the most decision-relevant capital and liquidity information for the Company and Hong Kong Branch is still absent. A sudden change in the issuer assessment appears less likely than a change in security-level sentiment if new information reveals reduced Hong Kong RBC headroom, investment losses, policyholder outflows or greater reliance on subordinated capital.

The FY2025 Macau Branch filing modestly strengthens confidence in the local operating franchise. MOP12.95bn of premium business income, MOP1.23bn of after-tax profit and MOP100.64bn of assets show that the Macau operation is material and profitable. However, its account presentation also reinforces the insurance-specific risk framework: technical provisions, policyholder balances, reinsurance and investment results dominate the balance sheet and earnings. The absence of detailed portfolio, liability and capital information means that the filing supports the credit floor through franchise evidence but does not lift the credit ceiling through demonstrated group-wide capital headroom.

For the Company, the most important supports remain the China Life franchise, the regional scale of the insurance operations, strategic group relevance and A-range external ratings. The principal constraints are public-data limitations after 2022 for detailed Company financials, current Hong Kong RBC and capital composition, the quality and liquidity of investment assets, policyholder behaviour and full rating-agency rationale. The audited Macau Branch numbers should be incorporated into the evidence base, but never labelled as consolidated Company or Hong Kong Branch figures.